High dose chemotherapy and autologous stem cell transplantation (BMT) is widely used in the treatment of advanced breast cancer. However, the procedure is followed by a high relapse rate, and its overall efficacy and place in the treatment of breast cancer of varying stages is still evolving. We have developed approaches for induction of a graft versus tumor (GVT) effect following autologous BMT. Our preclinical studies have shown that incubation of peripheral stem cells (PBSC) with Interleukin-2 (IL-2) in vitro leads to the generation of killer cells within the PBSC population. BMT with these activated cells (APC) followed by IL-2 therapy induces a GVT effect in animal models, which appears to correlate with certain immunological changes. We have already initiated a phase I clinical protocol based upon these results in patients with stage Il, III, and IV breast cancer. Interestingly, these patients have circulating cells capable of lysing tumor and also have evidence on biopsy of autologous graft versus host disease (GVH) even in visceral organs. We have also found that IL-2 activated primed peripheral blood stem cells will engraft within 10-12 days. Thus, we have been able to translate our initial preclinical and animal model results into the clinic. This proposal aims to investigate the efficacy of this approach in a randomized trial of high dose chemotherapy plus """"""""activated"""""""" PBSC and the optimum IL-2 regimen versus high dose chemotherapy plus standard PBSC in which the primary comparison is disease-free survival time and the incidence of GVH will be evaluated. We will also evaluate the mechanisms and interrelationships between GVH and GVT with respect to cell phenotype, T-cell receptors and cytokines induced, similar to our studies in the animal model.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058185-08S1
Application #
6396834
Study Section
Project Start
1999-09-22
Project End
2003-08-31
Budget Start
Budget End
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Sharif, G M; Schmidt, M O; Yi, C et al. (2015) Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling. Oncogene 34:5879-89
Rosenfield, Sonia M; Bowden, Emma T; Cohen-Missner, Shani et al. (2012) Pleiotrophin (PTN) expression and function and in the mouse mammary gland and mammary epithelial cells. PLoS One 7:e47876
Wellstein, Anton; Toretsky, Jeffrey A (2011) Hunting ALK to feed targeted cancer therapy. Nat Med 17:290-1
Hu, Zhang-Zhi; Kagan, Benjamin L; Ariazi, Eric A et al. (2011) Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS One 6:e20410
Stylianou, D C; Auf der Maur, A; Kodack, D P et al. (2009) Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28:3296-306
Coticchia, Christine M; Revankar, Chetana M; Deb, Tushar B et al. (2009) Calmodulin modulates Akt activity in human breast cancer cell lines. Breast Cancer Res Treat 115:545-60
Gibby, Krissa A; McDonnell, Kevin; Schmidt, Marcel O et al. (2009) A distinct role for secreted fibroblast growth factor-binding proteins in development. Proc Natl Acad Sci U S A 106:8585-90
Deb, Tushar B; Coticchia, Christine M; Barndt, Robert et al. (2008) Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation. Am J Physiol Cell Physiol 295:C365-77
Veselik, David J; Divekar, Shailaja; Dakshanamurthy, Sivanesan et al. (2008) Activation of estrogen receptor-alpha by the anion nitrite. Cancer Res 68:3950-8
Bullitt, Elizabeth; Lin, Nancy U; Smith, J Keith et al. (2007) Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology 245:824-30

Showing the most recent 10 out of 117 publications